Results 1 to 2 of 2

Thread: Expanded Access Program (Compassionate use) for VX-445 triple combo

  1. #1
    Super Moderator
    Join Date
    Sep 2016
    Posts
    134

    Expanded Access Program (Compassionate use) for VX-445 triple combo

    FYI- There's an expanded access program (EAP) compassionate use program available for the new triple combo, VX-445

    As far as I know, it's not limited to US patients. (I think Ireland and UK are included, but other countries may be eligible).

    It's difficult to get any information from Vertex.
    In the past, their expanded access program has been limited to patients who have eligible mutations and those with:
    FEV1 of less than 40% predicted OR decline of 20% predicted in a 6 month period and sustained for 1 month OR being evaluated for a lung transplant.
    But I don't know if the EAP requirements are the same for VX-445.

    https://www.vrtx.com/medicines/expan...s#how-it-works

    Unfortunately, you can't follow their instructions for finding out more about it by going to clinicaltrials.gov, because the EAP isn't listed as it's required to be, but you can e-mail them and ask about it.


    United States
    [email protected]

    Canada
    [email protected]

    Latin America
    [email protected]

    Africa, Asia, Australia and Europe
    [email protected]

    Here's some general info. about expanded access:
    https://www.fda.gov/news-events/publ...xpanded-access
    Last edited by jricci; 07-29-2019 at 09:27 AM. Reason: added link

  2. #2
    Super Moderator
    Join Date
    Sep 2016
    Posts
    134
    There's also a facebook group that you can join where people have been sharing their experiences with VX-445 Expanded Access
    https://www.facebook.com/groups/vx445compassionateuse/

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •